Amgen Backs Juno's Fed. Circ. Bid To Revive $1.1B Judgment
Biotech giant Amgen has joined forces with cancer research centers to back Bristol-Myers Squibb subsidiary Juno Therapeutics' efforts to restore a $1.1 billion patent judgment against Gilead's Kite Pharma that was...To view the full article, register now.
Already a subscriber? Click here to view full article